Esperion Therapeutics Cash Flow - Annual (NASDAQ:ESPR)

Add to My Stocks
$48.8 $1.09 (2.28%) ESPR stock closing price Jul 24, 2017 (Closing)

The cash flow statement is one of the reports a publicly traded company like Esperion Therapeutics needs to disclose. The profit-loss statement shows Esperion Therapeutics profits, the balance sheet shows Esperion Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Esperion Therapeutics stock analysis. Esperion Therapeutics had a negative net income cash flow of $-74.97M for the latest year. This report is very useful in measuring the short term viability of a company. Esperion Therapeutics has a negative cash and cash equivalents change of $-39.17M. View details of Esperion Therapeutics cash flows for latest & last ten financial years.

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011
Esperion Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.31M0.94M0.39M0.59M0.27M0.17M
Net Increase (Decrease) in Assets Liabilities9.98M-2.08M0.25M3.22M-0.84M0.8M
Cash From (used in) Discontinued Operations------
Other Adjustments Net15.95M12.77M3.71M4.15M0.04M0.08M
Esperion Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.3M-0.86M0.16M-0.01M
Acquisition Disposition of Subsidiaires------
Increase (Decrease) in Investments10.21M-159.76M-35.73M-21.17M-0.5M
Other Cash Inflow (Outflow) from Investment Activities------
Esperion Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares0.04M191.16M92.28M89.14M0.04M6.71M
Issuance (Repayment) of Debt Securities-1.6M-0.63M4.83M-15.41M-
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions------
Other Cash from (used by) Financing Activities
Esperion Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash------
Esperion Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year77.33M85.03M56.53M6.51M1.57M3.41M
Cash & Equivalents at Year End38.16M77.33M85.03M56.53M6.51M1.57M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

Esperion Therapeutics stock price history provides insight into historical stock price fluctuations, and Esperion Therapeutics stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:
  • Net Change in Cash and Cash Equivalents: Esperion Therapeutics cash reduced YoY to $-74.97M, meaning the company is unable to meet its expenditure and grow cash which will also eventually reflect in the Esperion Therapeutics stock price movement.
  • Esperion Therapeutics decreased its cash from operating activities to $9.58M in 2016. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-47.73M for ESPR in last year report.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-1.55M for Esperion Therapeutics.